Reporting and exclusion of sexual and gender minorities in cancer clinical trials

Int J Cancer. 2020 Apr 15;146(8):2360-2361. doi: 10.1002/ijc.32700. Epub 2019 Nov 1.

Authors

Ethan B Ludmir¹, Andres F Espinoza², Amit Jethanandani^{1

3}, Timothy A Lin^{1

2}, Walker Mainwaring², Austin B Miller⁴, Prajnan Das¹

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX.
² Baylor College of Medicine, Houston, TX.
³ The University of Tennessee Health Science Center College of Medicine, Memphis, TN.
⁴ The University of Texas Health Science Center McGovern Medical School, Houston, TX.

PMID: 31584188
DOI: 10.1002/ijc.32700

No abstract available

Publication types

Letter

MeSH terms

Clinical Trials, Phase III as Topic / methods
Clinical Trials, Phase III as Topic / statistics & numerical data*
Female
Humans
Male
Neoplasms / therapy*
Patient Selection
Randomized Controlled Trials as Topic / methods
Randomized Controlled Trials as Topic / statistics & numerical data*
Sexual and Gender Minorities / statistics & numerical data*